Clinical trials: Epithelial Tumor, Malignant
Malignant Glioma
Mapping of Electrical Properties in the Brain
This study evaluates imaging methods for monitoring neural and electrical activity in the brain for improving clinical diagnosis.
- Trial name
- NCT06470711
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Liver Malignant Tumors
Clinical Effectiveness of Microwave Ablation Using Starwave Microwave Generator for Hepatic Malignancies
The purpose of this study is to determine the technical success rate of creating a safety margin of 5 mm or more including the tumor by performing image-guided percutaneous microwave thermal therapy using a microwave generator…
- Trial name
- NCT06426992
- Testing
- Starwave Microwave Ablation System, Microwave Ablation, Ultrasound-CT fusion guidance system
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- Seoul National University Hospital
Hepatitis C, Hepatocellular Carcinoma
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
The primary objective is to determine if the administration of a combination of sofosbuvir (SOF; GS-7977; PSI-7977) and ribavirin (RBV) to HCV-infected adults with hepatocellular carcinoma (HCC) meeting the MILAN criteria prior…
- Trial name
- NCT01559844
- Testing
- Sofosbuvir, Ribavirin
- Where
- 15 sites in United States, New Zealand and 1 more
- Volunteers
- 61 people
- Sponsor
- Gilead Sciences
EGFR, Lung Cancer (NSCLC)
Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC
This study will evaluate the novel, oral EGFR TKI, zipalertinib, in the adjuvant ctDNA-adapted treatment of stage IA2 to IIIC atypical EGFR-mutant NSCLC after completion of definitive therapy with a primary endpoint of molecular…
- Conditions
- EGFR, Lung Cancer (NSCLC), Non Small Cell Lung Cancer
- Trial name
- NCT07802834
- Testing
- Zipalertinib
- Volunteers
- 42 people
- Sponsor
- Stanford University
Carcinoma, Hepatocellular
A Study Comparing Radiofrequency Ablation and Hepatic Resection for Hepatocellular Carcinoma
The purpose of this prospective randomized study is to compare the efficacy and safety of radiofrequency ablation and hepatic resection for small hepatocellular carcinomas with very homogeneous underlying conditions.
- Trial name
- NCT02482909
- Testing
- Hepatic resection, Radiofrequency ablation
- Volunteers
- 68 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma
Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma
Though hepatectomy is one of the curative treatment for patients with hepatocellular carcinoma (HCC), the 5-years recurrence-free survival is lower than 30%.
- Trial name
- NCT05221398
- Testing
- Immune Checkpoint Inhibitors Based Adjuvant therapy, Active surveillance
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Guangxi Medical University
Perihilar Cholangiocarcinoma
PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma
This is an open-label,single center,non-randomized,single arm exploratory study. The objective of this study is to evaluate the efficacy and safety of PD-1 antibody plus GEMOX as postoperative adjuvant therapy in perihilar…
- Trial name
- NCT05430698
- Testing
- PD-1antibody plus GEMOX
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Tongue Neoplasms, Carcinoma
Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line
In vitro study to examine whether luteolin and nano-luteolin exert an inhibitory effect on tongue squamous cell carcinoma cell line by inducing apoptosis, and to assess if nano-luteolin has more efficient apoptotic activity than…
- Trial name
- NCT03288298
- Testing
- luteolin, nano-luteolin
- Volunteers
- 4 people
- Sponsor
- Cairo University
Hepatitis C, Cirrhosis
Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV.
The main risk factor for development of hepatocellular carcinoma (HCC) is cirrhosis of any etiology, with an annual incidence risk between 1-6%; currently the leading cause of death in patients with cirrhosis and the 2nd cause of…
- Conditions
- Hepatitis C, Cirrhosis, Antiviral Drug Adverse Reaction
- Trial name
- NCT03775798
- Testing
- Direct antiviral agents for hepatitis C
- Where
- Argentina
- Volunteers
- 2,200 people
- Sponsor
- Austral University, Argentina
Breast Carcinoma, Neuropathy
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with peripheral neuropathy receiving chemotherapy for breast cancer.
- Trial name
- NCT02610439
- Testing
- Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 575 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer
Based on the existing research results, Osimertinibi is effective not only for patients with sensitizing EGFR mutations, but also for other less common EGFR mutations.
- Trial name
- NCT03460275
- Testing
- Osimertinib Mesylate Tablets
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Oral Squamous Cell Carcinoma, Neoadjvant Therapy
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
To evaluate the efficacy of neoadjuvant anti-PD-1 plus anti-VEGFR therapy for patients with locally advanced and resectable oral squamous cell carcinoma, and the CPS>10 in the biopsy samples.
- Conditions
- Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Anti-VEGFR
- Trial name
- NCT05069857
- Testing
- Camrelizumab (anti-PD-1 inhibitor), Apatinib (anti-VEGFR inhibitor)
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Non-Invasive Bladder Urothelial Carcinoma
Intravesical BCG: is the Urinary Bladder Ready to Receive it
Prospective cohort and Prospective observational study which aims To define the healing time-frame of the resected area of the bladder after TURBT.
- Trial name
- NCT05335512
- Volunteers
- 100 people
- Sponsor
- Tata Memorial Centre
Urothelial Carcinoma
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
This substudy is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new treatment options.
- Trial name
- NCT05562830
- Testing
- Zilovertamab vedotin, Pembrolizumab, MK-3120
- Where
- 28 sites in United States, Australia and 9 more
- Volunteers
- 48 people
- Sponsor
- Merck Sharp & Dohme LLC
Nasopharyngeal Carcinoma
HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA） for nasopharyngeal carcinoma.
- Trial name
- NCT02523430
- Testing
- interventional therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Non Small Cell Lung Cancer
A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with carboplatin and paclitaxel as first line therapy in subjects with advanced non-small cell lung cancer (NSCLC).
- Trial name
- NSCLC (NCT00583830)
- Testing
- Mapatumumab, Paclitaxel, Carboplatin
- Where
- 33 sites in United States, Germany and 2 more
- Volunteers
- 111 people
- Sponsor
- Human Genome Sciences Inc.
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
This phase II trial tests whether CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine (STEMVAC) works to shrink tumors in patients with stage IV non-small cell lung cancer.
- Trial name
- NCT05242965
- Testing
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Sargramostim, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Washington
Cervical Cancer Recurrent or Persistent, Palliative Treatment
Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma
This study evauates the global survival of patients following administration of mAb Nimotuzumab hR3 + chemotherapy in the treatment of cervical cancer in first line therapy, after relapsing from chemo-radiotherapy.
- Conditions
- Cervical Cancer Recurrent or Persistent, Palliative Treatment, Monoclonal Antibody in Cervical Cancer Treatment
- Trial name
- NCT02083211
- Testing
- mAb Nimotuzumab
- Where
- Mexico
- Volunteers
- 168 people
- Sponsor
- National Institute of Cancerología
Esophageal Squamous Cell Carcinoma
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus.
- Trial name
- NCT06780111
- Testing
- Pembrolizumab, I-DXd, Leucovorin
- Where
- 52 sites in United States, Brazil and 14 more
- Volunteers
- 298 people
- Sponsor
- Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma
SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC
This is a Phase II study of anti-nectin-4 ADC combined with the EGFR monoclonal antibody and the PD-1 monoclonal antibody in participants with advanced head and neck squamous cell carcinoma.
- Trial name
- NCT06989671
- Testing
- JMT101, SYS6002, SG001
- Volunteers
- 430 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.